{
  "source": "PA-Notification-Braftovi.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 1255-10\nProgram Prior Authorization/Notification\nMedication Braftovi® (encorafenib)\nP&T Approval Date 8/2018, 9/2019, 6/2020, 6/2021, 6/2022, 6/2023, 12/2023, 6/2024, 2/2025,\n6/2025\nEffective Date 9/1/2025\n1. Background:\nBraftovi® (encorafenib) is a kinase inhibitor indicated, in combination with Mektovi™\n(binimetinib), for the treatment of patients with unresectable or metastatic melanoma with a\nBRAF V600E or V600K mutation.\nBraftovi, in combination with Erbitux® (cetuximab) and mFOLFOX6 (fluorouracil, leucovorin,\nand oxaliplatin), is indicated for the treatment of patients with metastatic colorectal cancer\n(CRC) with a BRAF V600E mutation. Braftovi, in combination with Erbitux® (cetuximab), is\nindicated for the treatment of patients with metastatic CRC with a BRAF V600E mutation after\nprior therapy. The National Cancer Comprehensive Network (NCCN) Compendium\nrecommends the use of Braftovi, in combination with Erbitux or Vectibix (panitumumab), in\npatients with metastatic or advanced colorectal cancer with a BRAF V600E mutation.\nBraftovi, in combination with Mektovi, is also indicated for the treatment of adult patients with\nmetastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation. The NCCN\nCompendium also recommends the use of Braftovi, in combination with Mektovi for the\ntreatment of recurrent and advanced NSCLC with BRAF V600E mutation.\nLimitations of Use\nBraftovi is not indicated for the treatment of patients with wild-type BRAF melanoma, wild-type\nBRAF CRC, or wild-type BRAF NSCLC.\nCoverage Information:\nMembers will be required to meet the criteria below for coverage. For members under the age of\n19 years, the prescription will automatically process without a coverage review.\nSome states mandate benefit coverage for off-label use of medications for some diagnoses or\nunder some circumstances. Some states also mandate usage of other Compendium references.\nWhere such mandat",
    ".\nSome states mandate benefit coverage for off-label use of medications for some diagnoses or\nunder some circumstances. Some states also mandate usage of other Compendium references.\nWhere such mandates apply, they supersede language in the benefit document or in the\nnotification criteria.\n2. Coverage Criteriaa:\nA. Patients less than 19 years of age\n1. Braftovi will be approved based on the following criterion:\na. Patient is less than 19 years of age\nAuthorization will be issued for 12 months.\n© 2025 UnitedHealthcare Services, Inc.\n1\nB. Melanoma\n1. Initial Authorization\na. Braftovi will be approved based on all of the following criteria:\n(1) Diagnosis of melanoma\n-AND-\n(2) Presence of BRAF V600E mutation\n-AND-\n(3) Disease is one of the following:\n(a) Unresectable\n(b) Metastatic\n-AND-\n(4) Used in combination with Mektovi (binimetinib)\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Braftovi will be approved based on both of the following criteria:\n(1) Patient does not show evidence of progressive disease while on Braftovi therapy\n-AND-\n(2) Used in combination with Mektovi (binimetinib)\nAuthorization will be issued for 12 months.\nC. Colon/Rectal Cancer\n1. Initial Authorization\na. Braftovi will be approved based on all of the following:\n(1) Diagnosis of colon or rectal cancer\n-AND-\n(2) Presence of BRAF V600E mutation\n© 2025 UnitedHealthcare Services, Inc.\n2\n-AND-\n(3) Disease is one of the following:\n(a) Advanced\n(b) Metastatic\n-AND-\n(4) One of the following:\n(a) Both of the following:\ni. Patient has received prior therapy with an oxaliplatin-based regimen (e.g.,\nFOLFOX, CAPEOX)\n-AND-\nii. Used in combination with Erbitux (cetuximab) or Vectibix (panitumumab)\n-OR-\n(b) Both of the following:\ni. Patient has not received prior therapy with an oxaliplatin-based regimen\n(e.g., FOLFOX, CAPEOX)\n-AND-\nii. Used in combination with both of the following:\n• Erbitux (cetuximab) or Vectibix (panitumumab)\n-AND-\n• FOLFOX (fluorouracil, leucovorin, and oxaliplatin)\nAut",
    " regimen\n(e.g., FOLFOX, CAPEOX)\n-AND-\nii. Used in combination with both of the following:\n• Erbitux (cetuximab) or Vectibix (panitumumab)\n-AND-\n• FOLFOX (fluorouracil, leucovorin, and oxaliplatin)\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Braftovi will be approved based on both of the following criteria:\n(1) Patient does not show evidence of progressive disease while on Braftovi therapy\n-AND-\n(2) Used in combination with one of the following:\n(a) Erbitux (cetuximab)\n© 2025 UnitedHealthcare Services, Inc.\n3\n(b) Vectibix (panitumumab)\n(c) Erbitux (cetuximab) and FOLFOX (fluorouracil, leucovorin, and oxaliplatin)\n(d) Vectibix (panitumumab) and FOLFOX\nAuthorization will be issued for 12 months.\nD. Non-Small Cell Lung Cancer\n1. Initial Authorization\na. Braftovi will be approved based on all of the following criteria:\n(1) Diagnosis of non-small cell lung cancer (NSCLC)\n-AND-\n(2) Presence of BRAFV600 mutation\n-AND-\n(3) Disease is one of the following:\n(a) Advanced\n(b) Recurrent\n(c) Metastatic\n-AND-\n(4) Used in combination with Mektovi (binimetinib)\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Braftovi will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Braftovi therapy\n-AND-\n(2) Used in combination with Mektovi (binimetinib)\nAuthorization will be issued for 12 months.\nE. NCCN Recommended Regimens\nThe drug has been recognized for treatment of the cancer indication by The National\nComprehensive Cancer Network (NCCN) Drugs and Biologics Compendium with a Category of\nEvidence and Consensus of 1, 2A, or 2B\n© 2025 UnitedHealthcare Services, Inc.\n4\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific benefit\nplan coverage may also impact coverage criteria. Other policies and utilization management\nprograms may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHeal",
    "fic benefit\nplan coverage may also impact coverage criteria. Other policies and utilization management\nprograms may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10)\nand/or claim logic. Use of automated approval and re-approval processes varies by program\nand/or therapeutic class.\n• Supply limits may be in place.\n4. References:\n1. Braftovi [package insert]. Boulder, CO: Array BioPharma Inc.; December 2024.\n2. The NCCN Drugs and Biologics Compendium (NCCN Compendium®). Available at\nwww.nccn.org. Accessed April 30, 2025.\nProgram Prior Authorization/Notification - Braftovi (encorafenib)\nChange Control\n8/2018 New program\n9/2019 Annual review. Updated background and criteria to include NCCN\nrecommended use in BRAF V600 E colorectal cancer. Updated\nreferences. Added general NCCN recommended review criteria.\n6/2020 Updated background and criteria to include new indication of BRAF\nV600E mutated colorectal cancer. Modified criteria for BRAF V600E\nmutated colorectal cancer to also include NCCN recommended use which\nno longer requires concomitant Mektovi.\n6/2021 Annual review with no change to criteria. Updated reference.\n6/2022 Annual review. Added continuation of combination therapy to colon and\nrectal cancer. Updated background and references.\n6/2023 Annual review with no change to criteria. Added state mandate footnote.\nUpdated reference.\n12/2023 Updated background and criteria to include new FDA approved use in\nBRAF V600E NSCLC. Updated references.\n6/2024 Annual review. Updated language and formatting of criteria for\nmelanoma, colon cancer, and rectal cancer with no change in intent.\nAdded coverage for advanced and recurrent NSCLC per NCCN\nCompendium. Added reauthorization requirement for NSCLC that\nBraftovi is used in combination with Mektovi. Updated references.\n2/2025 Updated background and criteria to include ne",
    "rrent NSCLC per NCCN\nCompendium. Added reauthorization requirement for NSCLC that\nBraftovi is used in combination with Mektovi. Updated references.\n2/2025 Updated background and criteria to include new FDA approved use in\ncombination with Erbitux and mFOLFOX6 in BRAF V600E mutated\ncolorectal cancer.\n© 2025 UnitedHealthcare Services, Inc.\n5\n6/2025 Annual review. Combined criteria sections for colon and rectal cancer.\nUpdated initial and reauthorization criteria for colon and rectal cancer.\nUpdated background and references.\n© 2025 UnitedHealthcare Services, Inc.\n6"
  ]
}